MACROGENICS, INC. Deferred Tax Assets, Operating Loss Carryforwards, Domestic
MACROGENICS, INC. (MGNX) had Deferred Tax Assets, Operating Loss Carryforwards, Domestic of $136.48 million as of 2025-12-31, per its 10-K filed 2026-03-09.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross › Deferred Tax Assets, Operating Loss Carryforwards, Components
us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic · last filed 2026-03-09
- 2025-12-31: Deferred Tax Assets, Operating Loss Carryforwards, Domestic $136.48M.
- 2024-12-31: Deferred Tax Assets, Operating Loss Carryforwards, Domestic $116.34M.
- 2023-12-31: Deferred Tax Assets, Operating Loss Carryforwards, Domestic $140.71M.
- 2022-12-31: Deferred Tax Assets, Operating Loss Carryforwards, Domestic $163.07M.
| Period end | Deferred Tax Assets, Operating Loss Carryforwards, Domestic | Deferred Tax Assets, Operating Loss Carryforwards, Domestic as first filed |
|---|---|---|
| 2025-12-31 | $136.48M 10-K · filed 2026-03-09 | |
| 2024-12-31 | $116.34M 10-K · filed 2026-03-09 | |
| 2023-12-31 | $140.71M 10-K · filed 2025-03-20 | |
| 2022-12-31 | $163.07M 10-K · filed 2024-03-07 | |
| 2021-12-31 | $175.80M 10-K · filed 2023-03-15 | |
| 2020-12-31 | $136.09M 10-K · filed 2022-02-24 | |
| 2019-12-31 | $116.44M 10-K · filed 2021-02-25 | |
| 2018-12-31 | $87.28M 10-K · filed 2020-02-25 | |
| 2017-12-31 | $50.35M 10-K · filed 2019-02-26 | |
| 2016-12-31 | $75.38M 10-K · filed 2018-02-27 | |
| 2015-12-31 | $57.95M 10-K · filed 2017-02-28 | |
| 2014-12-31 | $55.36M 10-K · filed 2016-02-29 | |
| 2013-12-31 | $36.56M 10-K · filed 2015-03-03 | $36.56M 10-K · filed 2014-03-20 |
| 2012-12-31 | $35.33M 10-K · filed 2014-03-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |